Calreticulin as an Adjuvant In Vivo to Promote Dendritic Cell Maturation and Enhance Antigen-Specific T Lymphocyte Responses against Melanoma

Figure 2

In vivo administration of CRT/39-272 induce splenic cDC maturation and enhance OVA-specific T/B cell responses. C57BL/6 mice were treated with OVAp or OVAp-CRT for 21 days. (a) The MFI of CD40, CD80, and CD86 expression on the splenic CD11c⁺ cDCs was analyzed by flow cytometry. (b) Serum OVA-specific IgG concentrations were measured by ELISA. (c) ILN cells were obtained from the immunized mice on day 21, and CD4, CD8, CD44, and CD62L expressions on the ILN cells were analyzed by flow cytometry. The percentage of total CD4⁺ and CD8⁺ T cells and the T_CM and T_EM cells in CD4⁺ or CD8⁺ T cells. Data are representative of at least three independent experiments. . .

(a)

(b)

(c)